Treatment of gastrointestinal cytomegalovirus infection with twice- daily foscarnet: A pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS

Douglas T. Dieterich, Michael A. Poles, Edward A. Lew, Sarah Martin-Munley, Jeanne Johnson, David E. Nix, Michael J. Faust

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Ten patients with AIDS and cytomegalovirus (CMV) gastrointestinal infection were included in an open-label study to evaluate the safety, efficacy, and pharmacokinetics of 90 mg of intravenous foscarnet/kg of body weight twice daily accompanied by (pre)hydration of 500 to 750 ml. Efficacy was documented endoscopically, while safety was evaluated clinically by patient reports and physical and laboratory observation. The pharmacokinetics of foscarnet was evaluated after the first dose and following approximately 20 days of therapy. Nine patients (90%) responded histopathologically, nine (90%) responded endoscopically, and nine (90%) responded symptomatically to foscarnet therapy. Adverse events resulted in discontinuance of medication in the case of one patient. The mean maximal concentration was 621 μM following the first dose and 687 μM at steady state (P = 0.11). The apparent elimination rate constant and elimination half-life were not different between dose I and steady state. There were no significant changes in foscarnet excretion or renal clearance between dose I and steady state. The steady-state volume of distribution was 23.4 liters following the first dose and 19.0 liters at steady state (P < 0.002). Twice-daily foscarnet appeared to be safe and efficacious in the treatment of CMV gastrointestinal disease in this study, resulting in endoscopic or histologic improvement in 9 of the 10 (90%) patients. Minor changes in clearance and volume of distribution noted at steady state compared to single-dose administration are readily explained by study design, known information about foscarnet pharmacokinetics, and changes in body weight and creatinine clearance in the patients.

Original languageEnglish (US)
Pages (from-to)1226-1230
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume41
Issue number6
StatePublished - Jun 1997

Fingerprint

Foscarnet
Cytomegalovirus Infections
Acquired Immunodeficiency Syndrome
Pharmacokinetics
Safety
Therapeutics
Body Weight Changes
Gastrointestinal Diseases
Cytomegalovirus
Half-Life
Creatinine
Body Weight
Observation

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Treatment of gastrointestinal cytomegalovirus infection with twice- daily foscarnet : A pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS. / Dieterich, Douglas T.; Poles, Michael A.; Lew, Edward A.; Martin-Munley, Sarah; Johnson, Jeanne; Nix, David E.; Faust, Michael J.

In: Antimicrobial Agents and Chemotherapy, Vol. 41, No. 6, 06.1997, p. 1226-1230.

Research output: Contribution to journalArticle

Dieterich, Douglas T. ; Poles, Michael A. ; Lew, Edward A. ; Martin-Munley, Sarah ; Johnson, Jeanne ; Nix, David E. ; Faust, Michael J. / Treatment of gastrointestinal cytomegalovirus infection with twice- daily foscarnet : A pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS. In: Antimicrobial Agents and Chemotherapy. 1997 ; Vol. 41, No. 6. pp. 1226-1230.
@article{d2e020aa6eb34169b0b15c0bd2994935,
title = "Treatment of gastrointestinal cytomegalovirus infection with twice- daily foscarnet: A pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS",
abstract = "Ten patients with AIDS and cytomegalovirus (CMV) gastrointestinal infection were included in an open-label study to evaluate the safety, efficacy, and pharmacokinetics of 90 mg of intravenous foscarnet/kg of body weight twice daily accompanied by (pre)hydration of 500 to 750 ml. Efficacy was documented endoscopically, while safety was evaluated clinically by patient reports and physical and laboratory observation. The pharmacokinetics of foscarnet was evaluated after the first dose and following approximately 20 days of therapy. Nine patients (90{\%}) responded histopathologically, nine (90{\%}) responded endoscopically, and nine (90{\%}) responded symptomatically to foscarnet therapy. Adverse events resulted in discontinuance of medication in the case of one patient. The mean maximal concentration was 621 μM following the first dose and 687 μM at steady state (P = 0.11). The apparent elimination rate constant and elimination half-life were not different between dose I and steady state. There were no significant changes in foscarnet excretion or renal clearance between dose I and steady state. The steady-state volume of distribution was 23.4 liters following the first dose and 19.0 liters at steady state (P < 0.002). Twice-daily foscarnet appeared to be safe and efficacious in the treatment of CMV gastrointestinal disease in this study, resulting in endoscopic or histologic improvement in 9 of the 10 (90{\%}) patients. Minor changes in clearance and volume of distribution noted at steady state compared to single-dose administration are readily explained by study design, known information about foscarnet pharmacokinetics, and changes in body weight and creatinine clearance in the patients.",
author = "Dieterich, {Douglas T.} and Poles, {Michael A.} and Lew, {Edward A.} and Sarah Martin-Munley and Jeanne Johnson and Nix, {David E.} and Faust, {Michael J.}",
year = "1997",
month = "6",
language = "English (US)",
volume = "41",
pages = "1226--1230",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Treatment of gastrointestinal cytomegalovirus infection with twice- daily foscarnet

T2 - A pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS

AU - Dieterich, Douglas T.

AU - Poles, Michael A.

AU - Lew, Edward A.

AU - Martin-Munley, Sarah

AU - Johnson, Jeanne

AU - Nix, David E.

AU - Faust, Michael J.

PY - 1997/6

Y1 - 1997/6

N2 - Ten patients with AIDS and cytomegalovirus (CMV) gastrointestinal infection were included in an open-label study to evaluate the safety, efficacy, and pharmacokinetics of 90 mg of intravenous foscarnet/kg of body weight twice daily accompanied by (pre)hydration of 500 to 750 ml. Efficacy was documented endoscopically, while safety was evaluated clinically by patient reports and physical and laboratory observation. The pharmacokinetics of foscarnet was evaluated after the first dose and following approximately 20 days of therapy. Nine patients (90%) responded histopathologically, nine (90%) responded endoscopically, and nine (90%) responded symptomatically to foscarnet therapy. Adverse events resulted in discontinuance of medication in the case of one patient. The mean maximal concentration was 621 μM following the first dose and 687 μM at steady state (P = 0.11). The apparent elimination rate constant and elimination half-life were not different between dose I and steady state. There were no significant changes in foscarnet excretion or renal clearance between dose I and steady state. The steady-state volume of distribution was 23.4 liters following the first dose and 19.0 liters at steady state (P < 0.002). Twice-daily foscarnet appeared to be safe and efficacious in the treatment of CMV gastrointestinal disease in this study, resulting in endoscopic or histologic improvement in 9 of the 10 (90%) patients. Minor changes in clearance and volume of distribution noted at steady state compared to single-dose administration are readily explained by study design, known information about foscarnet pharmacokinetics, and changes in body weight and creatinine clearance in the patients.

AB - Ten patients with AIDS and cytomegalovirus (CMV) gastrointestinal infection were included in an open-label study to evaluate the safety, efficacy, and pharmacokinetics of 90 mg of intravenous foscarnet/kg of body weight twice daily accompanied by (pre)hydration of 500 to 750 ml. Efficacy was documented endoscopically, while safety was evaluated clinically by patient reports and physical and laboratory observation. The pharmacokinetics of foscarnet was evaluated after the first dose and following approximately 20 days of therapy. Nine patients (90%) responded histopathologically, nine (90%) responded endoscopically, and nine (90%) responded symptomatically to foscarnet therapy. Adverse events resulted in discontinuance of medication in the case of one patient. The mean maximal concentration was 621 μM following the first dose and 687 μM at steady state (P = 0.11). The apparent elimination rate constant and elimination half-life were not different between dose I and steady state. There were no significant changes in foscarnet excretion or renal clearance between dose I and steady state. The steady-state volume of distribution was 23.4 liters following the first dose and 19.0 liters at steady state (P < 0.002). Twice-daily foscarnet appeared to be safe and efficacious in the treatment of CMV gastrointestinal disease in this study, resulting in endoscopic or histologic improvement in 9 of the 10 (90%) patients. Minor changes in clearance and volume of distribution noted at steady state compared to single-dose administration are readily explained by study design, known information about foscarnet pharmacokinetics, and changes in body weight and creatinine clearance in the patients.

UR - http://www.scopus.com/inward/record.url?scp=0030950677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030950677&partnerID=8YFLogxK

M3 - Article

C2 - 9174175

AN - SCOPUS:0030950677

VL - 41

SP - 1226

EP - 1230

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -